District of Delaware: IPR Estoppel Does Not Apply to Prior-Art Products

Jul 29, 2022

Reading Time : 2 min

The court initially noted that it was undisputed that the defendant could not have raised the prior-art products during a related IPR proceeding. However, the patentee had argued that the prior-art products at issue in the district court case were “cumulative” to the paper-based prior art that the defendant had asserted in the IPR proceeding. As such, the patentee argued that the defendant was still estopped from pursuing invalidity defenses based on the products. The court explained that although it had agreed to hear evidence on the cumulativeness of the prior-art products, the dispute could be settled without a hearing.

The court resolved the dispute by looking at the text of the estoppel statute and using “well-accepted canons of construction.” The court first explained that by the plain text of the statute, estoppel only applies to grounds that were raised or reasonably could have been raised during the IPR proceeding. Furthermore, even though the term “ground” was not defined in the statute, other courts had interpreted it to mean the “specific pieces of prior art” involved in the challenge. Adopting the same interpretation, the court reasoned that because prior-art products cannot not be raised in an IPR, such products cannot not be a “ground” that is subject to statutory estoppel.

The court acknowledged that the issue is not settled. Across the country, judges have reached varying conclusions, including a decision in which the former Chief Judge of the District of Delaware ruled that Section 315(e)(2) estoppel did apply to a prior-art product, given the circumstances of that case. Nevertheless, the court reasoned that adhering closely to the statutory text was the most appropriate course given that neither the Supreme Court nor the Federal Circuit has decided the issue.

The court also explained that Congress had chosen the statutory text after “considered debate and careful thought.” And because Congress could have provided broader categories of estoppel but did not do so, the court should not seek to create additional bases for estoppel.

Practice tip:

This decision highlights an on-going struggle among district courts about the scope of IPR estoppel. Until the scope is clarified, at least in the first instance by the Federal Circuit, parties should consider carefully whether estoppel might apply to invalidity grounds premised on prior-art products. Parties should look to decisions from within the district court and, more specifically, the presiding judge to determine how estoppel has been applied.

Chemours Co. FC LLC v. Daikin Indus., Ltd., 2022 WL 2643517, C.A. No. 17-1612 (MN) (D. Del. July 8, 2022)

Share This Insight

Previous Entries

IP Newsflash

May 07, 2026

The Northern District of Illinois granted a summary judgment motion of no invalidity based on indefiniteness because the qualitative terms like “sufficiently slow” and “desired period of time” were definite when viewed in light of the surrounding claim language and specification.

...

Read More

IP Newsflash

April 9, 2026

In the April 1, 2026 edition of the Official Gazette, the U.S. Patent and Trademark Office announced a new procedural framework that permits patent owners to submit a limited, early response to a request for ex parte reexamination.

...

Read More

IP Newsflash

March 12, 2026

The Northern District of Illinois recently dismissed a complaint without prejudice for failing to plausibly allege patent infringement. The court found that the allegations of direct infringement were insufficiently pled where the images of the accused product included in the complaint did not appear to show a particular necessary element of the claims.

...

Read More

IP Newsflash

March 12, 2026

The District of New Jersey recently denied the litigants’ request for a briefing schedule to resolve a dispute about a proposed discovery confidentiality order, and also denied extending the deadlines for the defendants’ invalidity and non-infringement contentions. At issue was the scope of the FDA and patent prosecution bars in the confidentiality order.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.